Cobimetinib is primarily used in the treatment of certain types of cancer, particularly melanoma. It is often prescribed in combination with another drug, vemurafenib, to enhance its effectiveness. This combination therapy targets specific genetic mutations in cancer cells, helping to slow down or stop the growth of tumors. It is especially effective for patients whose melanoma has a mutation in the BRAF gene. The drug works by inhibiting the activity of enzymes that promote cancer cell proliferation, making it a valuable option in targeted cancer therapy. Regular monitoring and management of potential side effects are essential during treatment.